FRANKLIN, Tenn. / May 08, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference, May 13-15, 2025, in Las Vegas, Nevada.
In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s website starting at 1:20 p.m. Central Time / 11:20 a.m. Pacific Time on Wednesday, May 14th, 2025.
The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2024, Acadia operated a network of 262 behavioral healthcare facilities with approximately 11,850 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Last Trade: | US$24.53 |
Daily Change: | 0.76 3.20 |
Daily Volume: | 2,714,959 |
Market Cap: | US$2.270B |
August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load